title: Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.
abstract: OBJECTIVE
  This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients.
  
  
  METHODS
  mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability.
  
  
  RESULTS
  In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported.
  
  
  CONCLUSIONS
  These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.
authors: Cardarelli Hospital, Naples, Italy.
authors: Mimma
authors: M
authors: Rizzo
authors: Gaetano
authors: G
authors: Facchini
authors: Clementina
authors: C
authors: Savastano
authors: Giuseppe
authors: G
authors: Di Lorenzo
authors: Luigi De
authors: LD
authors: Lucia
authors: Luigi
authors: L
authors: Maiorino
authors: Beniamino
authors: B
authors: Casale
authors: Giuseppe
authors: G
authors: Grimaldi
authors: Roberta
authors: R
authors: Formato
authors: Antonio
authors: A
authors: Febbraro
authors: Giacomo
authors: G
authors: Cartenì
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D018572:Disease-Free Survival; D000068338:Everolimus; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus
keywords: everolimus; mRCC; observational studies; second-line therapy